In IPWatchdog, CFJ's Jeffrey Depp argues that the EU's Digital Markets Act turns Google's intellectual property into a utility for its rivals.

In Truth on the Market, we argued that a brain-injury blood test's 20-year road to patients shows why Congress must fix patent eligibility law.

Jeffrey Depp joins a Federalist Society panel with Alden Abbott, Jane Bambauer and Satya Marar on intellectual property, AI training and fair use.

In IPWatchdog, CFJ's Jeffrey Depp argues that by taking Hikma v. Amarin, the Supreme Court chose a narrow skinny-label fight over the patent questions that matter.

In Truth on the Market, CFJ's Jeffrey Depp argues that Hikma v. Amarin reflects a fatal conceit: the belief that courts and regulators can engineer cheaper drugs.

American technological leadership results from secure property rights driving risk taking not from centralized planning or regulatory micromanagement.

These proposed reforms—particularly the restrictions on serial and parallel inter partes review (“IPR”) challenges and the requirement that petitioners stipulate to litigating validity in only one forum—represent an urgently needed course-correction to restore reliability to U.S. patent rights, strengthen American innovation, and fortify the nation’s technological leadership against foreign adversaries, especially the People’s Republic of China.

In RealClearMarkets, CFJ's Jeffrey Depp argues that the EU's Digital Markets Act punishes scale and success and stifles the innovation Europe says it wants.

In Truth on the Market, CFJ's Jeffrey Depp argues that NIH's “access plan” mandate for patent licenses is central planning that threatens biomedical innovation.